Person:
ZORLU, MEHMET

Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
MEHMET
Last Name
ZORLU
Name
Email Address
Birth Date

Filters

2013 - 2019142020 - 20222
Reset filters

Settings

Author: KARATOPRAK, CUMALİ × Has files: true ×

Search Results

Now showing 1 - 10 of 16
  • Thumbnail Image
    PublicationOpen Access
    Assessment of serum endocan levels in patients with beta-thalassemia minor
    (2022-02-01T00:00:00Z) Zorlu, Mehmet; Ozer, Ömer Faruk; Karatoprak, Cumali; Kıskaç, Muharrem; Çakırca, Mustafa; ZORLU, MEHMET; ÖZER, ÖMER FARUK; KARATOPRAK, CUMALİ
    Objective: Beta-thalassemia minor is a blood disease caused by a hereditary decrease in beta-globin synthesis, frequently leading to hypochromic microcytic anemia. Formerly called endothelial cell-specific molecule 1, endocan is a proteoglycan released by vascular endothelial cells in many organs. Our aim was to investigate the relationship between the beta-thalassemia minor patients and the healthy control group in terms of serum endocan level. Methods: The study was performed in a total of 80 subjects. They were divided into two groups, the beta-thalassemia minor group (n=40) and the healthy control group (n=40). Serum endocan levels, age, sex, body mass index value, and tobacco use data of these groups were compared. Results: No statistically significant difference was detected between the two groups in terms of age, sex, and body mass index values (p>0.05). Endocan levels were measured to be 206.85±88.1 pg/mL in the beta-thalassemia minor group and 236.1±162.8 pg/mL in the control group with no significant difference between the groups in terms of serum endocan levels (p>0.05). Conclusions: In our study, there was no change in endocan level in beta-thalassemia minor. This might be because serum endocan levels are affected by multi-factorial reasons. Serum endocan levels may be altered secondarily to decreased beta-globin chain, increased sympathetic activity due to anemia, or platelet dysfunction induced by oxidative stress in beta-thalassemia minor. Further multicenter studies involving more patients are necessary to demonstrate this.
  • Thumbnail Image
    PublicationOpen Access
    CD40 ligand and P-selectin in heterozygous Beta-thalassemia
    (2016-06-01) CIKRIKCIOGLU, Mehmet Ali; SOYTAS, Rabia Bag; KILIC, Elif; Toprak, Aybala Erek; Karatoprak, CUMALİ; Zorlu, MEHMET; Kiskac, MUHARREM; EMEGIL, Sebnem; Cetin, GÜVEN; Dogan, ELİF ECE; SEKIN, Yahya; HAMDARD, Jamshid; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; KISKAÇ, MUHARREM; ÇETİN, GÜVEN; DOĞAN, ELİF ECE; KARATOPRAK, CUMALİ
    Objective: To investigate platelet functions and measure soluble CD40 ligand, soluble P-selectin, beta-thromboglobulin and platelet factor 4 levels in the blood of heterozygous beta thalassemia patients. Methods: The cross-sectional case-control study was conducted at Bezmialem Vakif University, Istanbul, Turkey, between September 2013 and April 2014, and comprised heterozygous beta thalassemia patients who were compared with 41 gender-, age- and body mass index-matched controls for platelet function markers. The two groups were also compared for co-morbidities, smoking, and regular medications. Results: Of the 78(78.78) subjects, 50(64%) were women and 28(36%) men with an overall mean age of 39.4±12.7 years (range: 18-79 years). The mean body mass index was 26.3±4.2. The heterozygous beta thalassemia group included 37(47%) subjects [24(65%) females; 13(35%) males] while the control group had 41(53%) [26(63%) females; 15(37%) males]. Soluble CD40 ligand and soluble P-selectin were lower in the heterozygous beta thalassemia group (p=0.009; p=0.010). Beta-thromboglobulin and platelet factor 4 levels were comparable between the groups (p=0.497; p=0.507.). Conclusions: Some platelet functions may be reduced in heterozygous beta thalassemia patients, which may be related to their lower incidence of cerebral and cardiac ischaemic events.
  • Thumbnail Image
    PublicationOpen Access
    Serum endocan levels in women with restless legs syndrome.
    (2015-11-19) CELIK, K; ÇıKRıKÇıOĞLU, MA; HALAC, G; KILIC, ERDEM; AYHAN, S; OZARAS, N; Karatoprak, CUMALİ; YILDIZ, KEMALETTİN; YILDIZ, RS; ZORLU, MEHMET; CAKIRCA, MUSTAFA; KıSKAÇ, MUHARREM; KILIÇ, ERDEM; YILDIZ, KEMALETTİN; ZORLU, MEHMET; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREM
    Background: Endocan is a recently introduced marker of endothelial dysfunction. The objective of this study was to compare serum endocan levels in patients with restless legs syndrome (RLS) and control subjects in order to elucidate whether RLS is associated with endothelial dysfunction. Methods: A total of 31 drug naïve female patients with RLS and 31 age- and BMI-matched women were included in the study. Patients with pathological or physiological conditions or with a history of medication use that could potentially influence endothelial functions were excluded, as well as those with alcohol or drug abuse history. The two groups were compared with routine blood tests and serum endocan levels. Results: Patients with RLS had lower serum endocan levels than the controls (P=0.037). There was a negative bivariate correlation between RLS severity score and serum endocan levels (r=-0.406, P=0.023). While white blood cell count was significantly higher in RLS group, 25-hydroxy vitamin D3, vitamin B12, transferrin saturation rate, and HDL-cholesterol were significantly lower. Creatininemia and diastolic blood pressure were also marginally insignificantly lower in RLS group. Due to the presence of differences between two groups in these variables, a linear regression analysis was performed that showed a positive association between endocan and creatininemia (β=0.310, P=0.022), and a negative association between endocan and RLS (β=-0.502, P,0.001). Conclusion: The results of this study seem to suggest that patients with RLS may have better endothelial functions when compared with the general population and that these patients may be better protected against atherosclerosis
  • Thumbnail Image
    PublicationOpen Access
    Association of calcium channel blocker use with lower hemoglobin levels in chronic kidney disease
    (2013-09-01) Karatoprak, CUMALİ; CIKRIKCIOGLU, M. A.; Cakirca, MUSTAFA; Kiskac, MUHARREM; Zorlu, MEHMET; Cetin, GÜVEN; YILDIZ, KEMALETTİN; ERKOC, R.; ALAY, M.; Erkal, S.; Erkal, S. N.; DOGAN, S.; Kazancioglu, RÜMEYZA; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇETİN, GÜVEN; YILDIZ, KEMALETTİN; KAZANCIOĞLU, RÜMEYZA
    Aim: To search whether calcium channel blockers (CCBs) are associated with lower hemoglobin levels in chronic kidney disease (CKD) patients who are not on renal replacement therapy (RRT), vitamin D and anti-anemic treatment. Patients and methods: CKD patients were classified into two groups. Patients on CCBs treatment (103 patients) and patients not using CCBs (104 patients) were compared cross-sectionally regarding clinical findings, complete blood count (CBC), biochemistry and regular medication use. Patients with polycystic kidney disease, comorbidities that could influence CBC other than iron deficiency of obscure origin, patients receiving RRT, erythropoietin (EPO), vitamin D, phosphate binders and drugs that could influence CBC were excluded. Under dependent variable of CCB use, all significantly different independent variables were subjected to multivariate binary logistic regression analysis (MBLRA). Results: Lower hemoglobin, lower bilirubinemia, higher serum EPO, higher systolic blood pressure were observed in CCB users. Two groups were similar concerning age, gender, BMI, CKD etiology, CKD stage, pretibial edema prevalence, cardiothoracic index, diastolic blood pressure, corrected reticulocyte count, BUN, creatinine, eGFR, proBNP, parathormone, alkaline phosphatase, phosphorous, corrected calcemia, sCRP, relative EPO deficiency and prevalence of relative EPO deficient patients. Groups were comparable regarding comorbidities, types and usage frequencies of all antihypertensive medications other than CCBs. Higher systolic blood pressure and lower hemoglobin were significantly associated with CCB use after MBLRA. Conclusions: Hemoglobin was significantly lower in CCB users compared to non-users, among CKD patients who did not receive RRT, EPO, phosphate binders, vitamin D, iron, vitamin B12 and folic acid.
  • Thumbnail Image
    PublicationOpen Access
    An Iron Deficiency Anemia Case That Came with Raw Rice Consumption
    (2015-02-01) ÇAMLI, AHMET ADİL; KARATOPRAK, CUMALİ; ÇETİN, GÜVEN; ZORLU, MEHMET; ALAY, MURAT; ÇAMLI, AHMET ADİL; KARATOPRAK, CUMALİ; ÇETİN, GÜVEN; ZORLU, MEHMET
    Pica is the chronic consumption of edible or nonedible materials that is thought to be caused by mental problems, pregnancy, or anemia. We wanted to report this case, which we have not seen in the literature before, of a pica patient who consumed raw rice due to iron deficiency anemia. A 26-year-old female patient was brought to the internal medicine polyclinic by her mother with complaints of consuming a bowl of raw rice (200 gr) every evening. The patient was treated with parenteral ferik hydroxide + sucrose complex (2700 mg) for 5 days. After 15 days, when she came to control her will to eat raw rice had been lost completely. As a result, the attention of doctors and family members for pica due to treatable causes, such as anemia, will prevent many probable complications.
  • Thumbnail Image
    PublicationOpen Access
    An evaluation of the relationship between vitamin D level and CTRP-9, tumor necrosis factor-alpha, thiol-disulfide hemostasis in women
    (2021-01-01T00:00:00Z) KISKAÇ, MUHARREM; ŞEKERCİ, ABDÜSSELAM; Guler, Eray Metin; TUNÇ, MUHAMMED; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; KISKAÇ, MUHARREM; ŞEKERCİ, ABDÜSSELAM; TUNÇ, MUHAMMED; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ; ZORLU, MEHMET
    Objective: Many chronic diseases such as malignancy, cardiovascular diseases, endothelial dysfunction, and autoimmune diseases, which have been shown to be related to vitamin D in various studies; have similar relations with CTRP-9, TNFα, and thiol-disulfide hemostasis. We aimed to contribute to the literature by evaluating the relationship between CTRP-9, TNFα, and thiol-disulfide hemostasis and vitamin D levels, which we thought may have some effects on the pathogenesis of vitamin D deficiency. Methods: In our study, 78 female volunteers older than 18 years were included. Volunteers were divided into three groups according to the reference values of vitamin D levels. Biochemical parameters, CTRP-9, TNFα, and thiol/disulfide hemostasis tests taken from all volunteers were studied. Results: In this study, there was a significant difference in CTRP-9, TNFα, total thiol (TT), native thiol (NT), DIS (disulfide), TT/DIS, and NT/DIS levels in vitamin D groups (p<0.05). There was a significant negative correlation between vitamin D and TNFα and DIS, while a significant positive correlation was found with CTRP-9, TT, NT, TT/DIS, and NT/DIS (p<0.05). Conclusions: It was determined that vitamin D deficiency causes a significant decrease in CTRP-9 level and a significant increase in TNFα level, as well as an increase in thiol/disulfide hemostasis in favor of disulfide, which may be a risk factor for increased oxidative stress. We considered that these changes may play mediator roles for many chronic diseases and metabolic disorders that are increasing in frequency due to vitamin D deficiency.
  • Thumbnail Image
    PublicationOpen Access
    Vildagliptin Treatment on the Portal Venous Pressure and Hepatosteatosis in Patients with Type 2 Diabetes Mellitus
    (2018-01-01) Kilicarslan, Rukiye; Cakirca, MUSTAFA; Aydin, SİNEM; OZKAN, Tuba; KOCAMAN, Orhan; Yolbas, Servet; Zorlu, MEHMET; Karatoprak, CUMALİ; Kiskac, MUHARREM; CIKRIKCIOGLU, Mehmet Ali; ERKOC, Reha; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; AYDIN, SİNEM; ZORLU, MEHMET; KISKAÇ, MUHARREM
    Objective: This study investigated how vildagliptin (a di-peptidyl peptidase 4 inhibitor) affects portal vein pressure and hepatosteatosis in patients with type 2 diabetes mellitus.
  • Thumbnail Image
    PublicationOpen Access
    The relationship between the atherosclerotic cardiovascular disease risk score used in the prediction of cardiovascular disease risk and endocan.
    (2019-05-01T00:00:00Z) Cakirca, M; Tunc, M; Zorlu, M; Dae, SA; Kiskac, M; Karatoprak, CUMALİ; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; TUNÇ, MUHAMMED; KARATOPRAK, CUMALİ
    Objective: To date, there have been no studies investigating whether or not there is a correlation between the serum endocan level and the atherosclerotic cardiovascular disease (ASCVD) risk score that is frequently used in the determination of the risk of cardiovascular disease. If a single parameter such as endocan can provide reliable results which could be used in the prediction of the cardiovascular disease risk, the workload of the clinician would be lightened. The aim of this study was to investigate whether or not there is an association between the serum endocan level and the ASVCD risk score. Materials and methods: This prospective, cross-sectional study included individuals age 40-79 years with risk factors calculated using the ASVCD score and individuals without any of those risk factors. In accordance with ASCVD risk calculation, each participant was questioned with respect to age, gender, height, weight, and lifestyle habits such as smoking, diseases, and medications. Systolic blood pressure, diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and serum endocan levels were measured and recorded. The serum endocan levels and ASCVD scores were compared. Results: The study included 205 individuals, comprising 92 (44.9%) males and 113 (55.1%) females with a mean age of 50.7 ± 7.6 years. The 10-year atherosclerosis risk was determined as mean 6.32% ± 5.9% (range, 0.3%-27.3%). The mean serum endocan level was calculated as 1109.6 ± 1479.7 ng/mL. As the ASCVD risk score increased, no increase was detected in the serum endocan level. Conclusion: The results of the study suggested that the serum endocan level is not suitable for use in place of the ASCVD risk score as a predictor of cardiovascular disease risk.
  • Thumbnail Image
    PublicationOpen Access
    GAS6 intron 8 c.834 + 7G &gt; A gene polymorphism in diabetic nephropathy.
    (2015-06-01) ERKOÇ, R; ÇıKRıKÇıOĞLU, MA; AINTAB, E; TOPRAK, ALİ; KILIC, U; GOK, O; CETIN, AI; ZORLU, MEHMET; KıSKAÇ, MUHARREM; CAKIRCA, MUSTAFA; Karatoprak, CUMALİ; ISEN, HC; ZORLU, MEHMET; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ
    Background - Aim: In animal experiments, growth arrest-specific 6 (Gas6) protein plays a key role in the development of mesangial cell and glomerular hypertrophy in the early phase of diabetic nephropathy, and diabetic nephropathy is prevented by warfarin-induced inhibition of GAS6 protein. It was shown that GAS6 intron 8 c.834+7G>A polymorphism is protective against type 2 diabetes mellitus, and AA genotype is associated with higher blood levels of GAS6 protein. Our aim is to investigate whether this polymorphism is a risk factor for diabetic nephropathy in type 2 diabetes mellitus. Method: Eighty-seven patients with diabetic nephropathy were compared with 66 non-diabetic controls in terms of GAS6 intron 8 c.834+7G>A polymorphism. Patients with history of stroke, ischemic heart disease were excluded. Each patient was examined by the ophthalmologist to determine diabetic retinopathy. Results: Frequency of GG, GA and AA genotypes are similar in diabetic nephropathy and control groups according to GAS6 intron 8 c.834+7G>A polymorphism (p = 0.837). Rate of diabetic retinopathy was 54.02%. In the subgroup analysis, GA genotype was significantly more frequent than GG genotype in patients with diabetic retinopathy when compared to without diabetic retinopathy (p = 0.010). Conclusion: In our study, GAS6 intron 8 c.834+7G>A polymorphism was not associated with diabetic nephropathy in type 2 diabetes mellitus. However, heterozygous state of this polymorphism may be a risk factor for diabetic retinopathy in patients with diabetic nephropathy.
  • Thumbnail Image
    PublicationOpen Access
    Evaluation of the Relation between Vitamin D and Serum Omentin and Vaspin Levels in Women
    (2016-07-01) Zorlu, MEHMET; Kiskac, MUHARREM; Cakirca, MUSTAFA; Guler, E. M.; CELIK, K.; GULTEPE, I.; CIKRIKCIOGLU, M. A.; Kocyigit, ABDÜRRAHİM; ZORLU, MEHMET; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ; GÜLER, ERAY METİN; KOÇYİĞİT, ABDÜRRAHİM
    Introduction: Vitamin D deficiency is a common health problem seen worldwide. Adipokines released from adipose tissue play important roles in the control of appetite and satiety, modulation of body fat distribution, regulation of insulin sensitivity and secretion, control of blood pressure, and regulation of endothelial functions and inflammation. The aim of the present study is to investigate how vitamin D levels affect serum vaspin and omentin levels.